Please login to the form below

Not currently logged in

PharmaVentures increases its Asia-Pacific presence

Aki von Roy will be based in Auckland, New Zealand

edit-aki2Oxford, UK-headquartered advisory firm PharmaVentures has appointed Aki von Roy as an associate based in Auckland, New Zealand.

He has over 30 years experience in pharma and 16 years in biotech, and has been involved in 18 start up or merger ventures as director or investor.

Von Roy said: “I am delighted to join PharmaVentures, a firm with a proven track record in deal making.”

Formally he was the European president of Bristol-Myers Squibb (BMS), where he was responsible for $2.2bn in sales, more than 7,500 employees and around 40 subsidiaries. In 1997, he retired from BMS to establish RvR Associates, a private investment firm specialising in health and related matters.

Von Roy has also been chairman of private and publicly traded companies such as Genesis R&D, Phylogica, Vital Foods and Phytomedics and currently works as a venture partner at BioPacificVentures and an advisor to Direct Capital.

Fintan Walton, CEO of PharmaVentures, added: “Aki has a unique insight into innovative healthcare in the Asia-Pacific region and he will be a great benefit to both PharmaVentures and its clients.”

26th September 2014

From: Marketing



Featured jobs

Subscribe to our email news alerts


Add my company
Anatomy Health

We are a health information design consultancy focused on developing simple, accessible and inclusive patient communications. From evaluating existing patient...

Latest intelligence

Waking the sleeping giant
The lights are coming on for healthcare delivery in Africa...
How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...